Abbott India: Resignation of Sridhar Kadangode as CFO, Murari Ranganathan as Commercial Director - Women's Health, Metabolics and International Business
Mumbai: Abbott India has announced the resignation of Sridhar Kadangode as Chief Financial Officer of the Company and Murari Ranganathan as Commercial Director - Women’s Health, Metabolics and International Business of the Company, effective close of business hours of February 26, 2025 and February 25, 2025 respectively, to pursue opportunities outside the Company.
Medical Dialogues team had earlier reported that Namita Shah - Associate Director - New Product Introduction and Therapy Area Strategy, had tendered her resignation from employment of the Company with effect from the close of business hours of April 15, 2025.
Headquartered in Mumbai, Abbott India Limited, a publicly listed company and a subsidiary of Abbott Laboratories The Company offers medicines in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders and primary care.
Abbott India Limited is part of Abbott's global pharmaceutical business in India.
